ARCH-backed Au­to­bahn launch­es with $76M to re­build myelin and re­verse MS

For decades, drugs for mul­ti­ple scle­ro­sis — and there have been many — have been al­most ex­clu­sive­ly band-aids: in­hibitors de­signed to halt the dam­age be­fore it got worse, which it in­evitably and ir­repara­bly would.

But a cou­ple years ago, Kei­th Lenden, a se­r­i­al biotech en­tre­pre­neur and a new­ly-mint­ed part­ner at ARCH Ven­tures, drove up to Ore­gon Health & Sci­ence Uni­ver­si­ty, where over a se­ries of hour-long con­ver­sa­tions, pro­fes­sor Tom Scan­lan sketched out a new po­ten­tial plan of at­tack.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.